Caractérisation clinique et biologique de l’hyperprogression tumorale lors du blocage de la voie PD-1/PD-L1
Les anticorps bloquant les points de contrôle immunitaires modifient profondément la gestion des patients atteints de cancer. À la pointe de cette nouvelle classe d'agents anticancéreux, les anticorps anti-PD-1 / PD-L1 peuvent ainsi restaurer une réponse efficace des cellules T antitumorales. E...
Main Author: | Champiat, Stéphane |
---|---|
Other Authors: | Université Paris-Saclay (ComUE) |
Language: | fr |
Published: |
2019
|
Subjects: | |
Online Access: | http://www.theses.fr/2019SACLS040 |
Similar Items
-
Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis
by: Jong Yeob Kim, et al.
Published: (2019-11-01) -
Hyperprogression Under Immune Checkpoint-Based Immunotherapy—Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model
by: Mikolaj Kocikowski, et al.
Published: (2020-03-01) -
The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
by: Xueping Wang, et al.
Published: (2020-05-01) -
Is hyperprogressive disease a specific phenomenom of immunotherapy?
by: Marta Brambilla, et al.
Published: (2020-12-01) -
IFN-γ and CD38 in Hyperprogressive Cancer Development
by: Stefania Angelicola, et al.
Published: (2021-01-01)